Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
Whats New at the pCPA
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Entresto (sacubitril/valsartan)
pCPA File Number:
21423
Negotiation Status:
Concluded with an LOI
Indication(s):
Heart failure, NYHA class II or III
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CADTH Project Number:
SR0644
pCPA Engagement Letter Issued:
2022-08-17
Negotiation Process Concluded:
2022-08-17